The MPO-463G>A Polymorphism and Lung Cancer Risk: A Meta-Analysis Based on 22 Case-Control Studies

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yang, Jun Ping ^a   Wang, Wen Bo ^b   Yang, Xiao Xi ^b   Yang, Lei ^b   Ren, Li ^b   Zhou, Fu Xiang ^b   Hu, Liu ^b   He, Wei ^b   Li, Bai Yu ^b   Zhu, Yan ^b   Jiang, Huan Gang ^b   Zhou, Yun Feng ^b  

^a TONGREN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GUANINE; MYELOPEROXIDASE;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONFIDENCE INTERVAL; ETHNICITY; GENETIC ASSOCIATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; META ANALYSIS (TOPIC); POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MODELS, GENETIC; PEROXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84879274871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065778     Document Type: Article

References (43)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Pharoah PD, Dunning AM, Ponder BA, Easton DF, (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4: 850-860.
3. (2004) The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta GA.
4. Klebanoff SJ, (1999) Myeloperoxidase. Proc Assoc Am Physicians 111: 383-389.
5. Austin GE, Lam L, Zaki SR, Chan WC, Hodge T, et al. (1993) Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia 7: 1445-1450.
6. Arslan S, Pinarbasi H, Silig Y, (2011) Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Molecular Medicine Reports 4: 87-92.
7. Skuladottir H, Autrup H, Autrup J, Tjoenneland A, Overvad K, et al. (2005) Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years: A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer 48: 187-199.
8. Lu W, Qi J, Xing D, Tan W, Miao X, et al. (2002) Lung cancer risk associated with genetic polymorphism in myeloperoxidase (-463 G/A) in a Chinese population. Zhonghua zhong liu za zhi [Chinese journal of oncology] 24: 250-253.
9. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, et al. (2000) Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 60: 644-649.
10. London SJ, Lehman TA, Taylor JA, (1997) Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Research 57: 5001-5003.
11. Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, et al. (2009) Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genetics and Cytogenetics 195: 143-149.
12. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2008) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 29: 1164-1169.
13. Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, et al. (2008) CyP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer 60: 40-46.
14. Yang M, Choi Y, Hwangbo B, Lee JS, (2007) Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer 57: 135-142.
15. Park JH, Park JM, Kim EJ, Cha SI, Lee EB, et al. (2006) Myeloperoxidase-463G>A polymorphism and risk of primary lung cancer in a Korean population. Cancer Detection and Prevention 30: 257-261.
16. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, et al. (2006) CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis 27: 525-532.
17. Liu G, Zhou W, Wang LI, Park S, Miller DP, et al. (2004) MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Letters 214: 69-79.
18. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW, (2004) Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environmental and Molecular Mutagenesis 44: 74-82.
19. Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, et al. (2003) Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics 13: 729-739.
20. Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, et al. (2002) A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 37: 35-40.
21. Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, et al. (2002) Myeloperoxidase-463 (G->A) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc 77: 17-22.
22. Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, et al. (2002) Point: Myeloperoxidase (-463)G-> A polymorphism and lung cancer risk. Cancer Epidemiology Biomarkers & Prevention 11: 1550-1554.
23. Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, et al. (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: The MPO-463 A allele is associated with reduced risk for small cell lung cancer in smokers. International Journal of Cancer 102: 530-535.
24. Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, et al. (2001) Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Letters 164: 161-167.
25. Hua F, Wang J, Gu J, Li S, Liu H, et al. (2010) A meta analysis on the relationship between myeloperoxidase G-463A genetic polymorphisms and lung cancer susceptibility. Chinese Journal of Lung Cancer 13: 122-127.
26. Chu HY, Wang ML, Wang MM, Gu DY, Wu DM, et al. (2010) The MPO-463G>A polymorphism and cancer risk: a meta-analysis based on 43 case-control studies. Mutagenesis 25: 389-395.
27. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
28. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
29. Galbraith RF, (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Statistics in Medicine 7: 889-894.
30. Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H, et al. (2009) More than numbers: The power of graphs in meta-analysis. American Journal of Epidemiology 169: 249-255.
31. Patsopoulos NA, Evangelou E, Ioannidis JP, (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. International Journal of Epidemiology 37: 1148-1157.
32. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
33. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
34. Sterne JA, Gavaghan D, Egger M, (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53: 1119-1129.
35. Chan EC, Lam SY, Fu KH, Kwong YL, (2005) Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genetics and Cytogenetics 162: 10-20.
36. Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, et al. (2002) Counterpoint: the myeloperoxidase-463G->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 11: 1555-1559.
37. Marchand LL, Seifried A, Lum A, Wilkens LR, (2000) Association of the myeloperoxidase-463G-> A polymorphism with lung cancer risk. Cancer Epidemiology Biomarkers and Prevention 9: 181-184.
38. Feig DI, Reid TM, Loeb LA, (1994) Reactive oxygen species in tumorigenesis. Cancer Res 54: 1890s-1894s.
39. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, et al. (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271: 14412-14420.
40. Chu H, Wang M, Wang M, Gu D, Wu D, et al. (2010) The MPO -463G>A polymorphism and cancer risk: a meta-analysis based on 43 case-control studies. Mutagenesis 25: 389-395.
41. (2006) The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta GA.
42. Van Helden YG, Keijer J, Knaapen AM, Heil SG, Briede JJ, et al. (2009) Beta-carotene metabolites enhance inflammation-induced oxidative DNA damage in lung epithelial cells. Free Radic Biol Med 46: 299-304.
43. Van Schooten FJ, Boots AW, Knaapen AM, Godschalk RW, Maas LM, et al. (2004) Myeloperoxidase (MPO)-463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev 13: 828-833.